Hydrated

Nidran is a cytostatic used in oncology

*Nidran* is a powerful cytostatic drug developed by the Japanese pharmaceutical company Sankyo Co. for the treatment of various types of cancer. The drug belongs to the group of nitrosoguanidines (tigazol or datolyse) and triazene. It is used to treat malignant neoplasms such as gliomas, leukemia, melanoma, skin, lung, gastrointestinal, liver and colon cancers.

Therapy can be carried out either as a single administration or in repeated courses, which are repeated at intervals of three to four weeks. The recommended dose is 30 mg/m² every two weeks for three months. The optimal dose must be calculated individually for each patient based on the size of the tumor and its type. Therapeutic